Global Biosimilar Insulin Lispro 麻豆原创 Research Report 2024

Publication ID:

PB505252031

Publication Date:

May 10, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Insulin lispro Sanofi is a 'biosimilar medicine'. This means that it is highly similar to a biological medicine (also known as the 'reference medicine') that is already authorised in the European Union (EU). The reference medicine for Insulin lispro Sanofi is Humalog 100 U/ml solution
The global Biosimilar Insulin Lispro market was valued at US$ 511.6 million in 2023 and is anticipated to reach US$ 619 million by 2030, witnessing a CAGR of 2.8% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Biosimilar Insulin Lispro, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar Insulin Lispro.
Report Scope
The Biosimilar Insulin Lispro market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilar Insulin Lispro market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar Insulin Lispro manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Sanofi
Gan&Lee
Geropharm
Segment by Type
Pre-filled
Cartridge
Segment by Application
Hospital
Retail Pharmacy
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Biosimilar Insulin Lispro manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Biosimilar Insulin Lispro in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Biosimilar Insulin Lispro 麻豆原创 Overview
1.1 Product Overview and Scope of Biosimilar Insulin Lispro
1.2 Biosimilar Insulin Lispro Segment by Type
1.2.1 Global Biosimilar Insulin Lispro 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Pre-filled
1.2.3 Cartridge
1.3 Biosimilar Insulin Lispro Segment by Application
1.3.1 Global Biosimilar Insulin Lispro 麻豆原创 Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Global Biosimilar Insulin Lispro 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Biosimilar Insulin Lispro Revenue 2019-2030
1.4.2 Global Biosimilar Insulin Lispro Sales 2019-2030
1.4.3 Global Biosimilar Insulin Lispro 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Biosimilar Insulin Lispro 麻豆原创 Competition by Manufacturers
2.1 Global Biosimilar Insulin Lispro Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Biosimilar Insulin Lispro Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Biosimilar Insulin Lispro Average Price by Manufacturers (2019-2024)
2.4 Global Biosimilar Insulin Lispro Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Biosimilar Insulin Lispro, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Biosimilar Insulin Lispro, Product Type & Application
2.7 Biosimilar Insulin Lispro 麻豆原创 Competitive Situation and Trends
2.7.1 Biosimilar Insulin Lispro 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Biosimilar Insulin Lispro Players 麻豆原创 Share by Revenue
2.7.3 Global Biosimilar Insulin Lispro 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Biosimilar Insulin Lispro Retrospective 麻豆原创 Scenario by Region
3.1 Global Biosimilar Insulin Lispro 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Biosimilar Insulin Lispro Global Biosimilar Insulin Lispro Sales by Region: 2019-2030
3.2.1 Global Biosimilar Insulin Lispro Sales by Region: 2019-2024
3.2.2 Global Biosimilar Insulin Lispro Sales by Region: 2025-2030
3.3 Global Biosimilar Insulin Lispro Global Biosimilar Insulin Lispro Revenue by Region: 2019-2030
3.3.1 Global Biosimilar Insulin Lispro Revenue by Region: 2019-2024
3.3.2 Global Biosimilar Insulin Lispro Revenue by Region: 2025-2030
3.4 North America Biosimilar Insulin Lispro 麻豆原创 Facts & Figures by Country
3.4.1 North America Biosimilar Insulin Lispro 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Biosimilar Insulin Lispro Sales by Country (2019-2030)
3.4.3 North America Biosimilar Insulin Lispro Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Biosimilar Insulin Lispro 麻豆原创 Facts & Figures by Country
3.5.1 Europe Biosimilar Insulin Lispro 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Biosimilar Insulin Lispro Sales by Country (2019-2030)
3.5.3 Europe Biosimilar Insulin Lispro Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Biosimilar Insulin Lispro 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Biosimilar Insulin Lispro 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Biosimilar Insulin Lispro Sales by Country (2019-2030)
3.6.3 Asia Pacific Biosimilar Insulin Lispro Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Biosimilar Insulin Lispro 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Biosimilar Insulin Lispro 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Biosimilar Insulin Lispro Sales by Country (2019-2030)
3.7.3 Latin America Biosimilar Insulin Lispro Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Biosimilar Insulin Lispro 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Biosimilar Insulin Lispro 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Biosimilar Insulin Lispro Sales by Country (2019-2030)
3.8.3 Middle East and Africa Biosimilar Insulin Lispro Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Biosimilar Insulin Lispro Sales by Type (2019-2030)
4.1.1 Global Biosimilar Insulin Lispro Sales by Type (2019-2024)
4.1.2 Global Biosimilar Insulin Lispro Sales by Type (2025-2030)
4.1.3 Global Biosimilar Insulin Lispro Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Biosimilar Insulin Lispro Revenue by Type (2019-2030)
4.2.1 Global Biosimilar Insulin Lispro Revenue by Type (2019-2024)
4.2.2 Global Biosimilar Insulin Lispro Revenue by Type (2025-2030)
4.2.3 Global Biosimilar Insulin Lispro Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Biosimilar Insulin Lispro Price by Type (2019-2030)
5 Segment by Application
5.1 Global Biosimilar Insulin Lispro Sales by Application (2019-2030)
5.1.1 Global Biosimilar Insulin Lispro Sales by Application (2019-2024)
5.1.2 Global Biosimilar Insulin Lispro Sales by Application (2025-2030)
5.1.3 Global Biosimilar Insulin Lispro Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Biosimilar Insulin Lispro Revenue by Application (2019-2030)
5.2.1 Global Biosimilar Insulin Lispro Revenue by Application (2019-2024)
5.2.2 Global Biosimilar Insulin Lispro Revenue by Application (2025-2030)
5.2.3 Global Biosimilar Insulin Lispro Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Biosimilar Insulin Lispro Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Sanofi
6.1.1 Sanofi Corporation Information
6.1.2 Sanofi Description and Business Overview
6.1.3 Sanofi Biosimilar Insulin Lispro Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Sanofi Biosimilar Insulin Lispro Product Portfolio
6.1.5 Sanofi Recent Developments/Updates
6.2 Gan&Lee
6.2.1 Gan&Lee Corporation Information
6.2.2 Gan&Lee Description and Business Overview
6.2.3 Gan&Lee Biosimilar Insulin Lispro Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Gan&Lee Biosimilar Insulin Lispro Product Portfolio
6.2.5 Gan&Lee Recent Developments/Updates
6.3 Geropharm
6.3.1 Geropharm Corporation Information
6.3.2 Geropharm Description and Business Overview
6.3.3 Geropharm Biosimilar Insulin Lispro Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Geropharm Biosimilar Insulin Lispro Product Portfolio
6.3.5 Geropharm Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Biosimilar Insulin Lispro Industry Chain Analysis
7.2 Biosimilar Insulin Lispro Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Biosimilar Insulin Lispro Production Mode & Process
7.4 Biosimilar Insulin Lispro Sales and 麻豆原创ing
7.4.1 Biosimilar Insulin Lispro Sales Channels
7.4.2 Biosimilar Insulin Lispro Distributors
7.5 Biosimilar Insulin Lispro Customers
8 Biosimilar Insulin Lispro 麻豆原创 Dynamics
8.1 Biosimilar Insulin Lispro Industry Trends
8.2 Biosimilar Insulin Lispro 麻豆原创 Drivers
8.3 Biosimilar Insulin Lispro 麻豆原创 Challenges
8.4 Biosimilar Insulin Lispro 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Sanofi
Gan&Lee
Geropharm

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.